CorMedix Stock (NASDAQ:CRMD)
Previous Close
$10.91
52W Range
$2.89 - $13.85
50D Avg
$9.63
200D Avg
$5.86
Market Cap
$671.70M
Avg Vol (3M)
$1.17M
Beta
1.58
Div Yield
-
CRMD Company Profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
CRMD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| GOSS | Gossamer Bio, Inc. |
| ALDX | Aldeyra Therapeutics, Inc. |
| TVTX | Travere Therapeutics, Inc. |
| INBX | Inhibrx Biosciences, Inc. |
| REPL | Replimune Group, Inc. |
| APTO | Aptose Biosciences Inc. |
| LIAN | LianBio |
| ETON | Eton Pharmaceuticals, Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| KRON | Kronos Bio, Inc. |
| ELDN | Eledon Pharmaceuticals, Inc. |
| PGEN | Precigen, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| TARS | Tarsus Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |